Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Spago Nanomedical is a public company listed on AktieTorget. Here you will find the latest press releases and financial information. Please contact us for further information.

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation.

Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired.

The Sarsia Seed Management team comes from a wide variety of backgrounds with a collective expertise which is extensive not only with respect to the various investment areas on which the fund focuses, but also with respect to best practice/effective fund administration.